Product Details
Neupogen
Filgrastim480 mcg/1.6 mL (300 mcg/mL)
Solution for Injection
1.6-mL Single-Use Vial (Preservative-Free)
DIN/PIN/NPN
09853464
Manufacturer
Amgen Canada Inc.
Formulary Listing Date
2026-01-30
Unit Price
281.8120
Amount MOH Pays
281.8120
Coverage Status
Exceptional Access Program Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
L03AA02
Interchangeable Products
NOLU Clinical Criteria
NORequirements
EAP Criteria
| Therapeutic Class | Reimbursement Criteria |
|---|---|
| Oncology – Supportive Management | Filgrastim [Granulocyte colony stimulating factor (G-CSF)]
Effective August 30, 2017, Exceptional Access Program (EAP) requests for Neupogen (filgrastim) will no longer be accepted for any indication. Patients who have an existing EAP approval for Neupogen can continue to receive Neupogen for the duration of the EAP approval period. Neupogen and Grastofil are not interchangeable products. As of August 30, 2017, new prescriptions for filgrastim for ODB eligible patients will be dispensed Grastofil, unless it specifies Neupogen with the appropriate LU code. Refer to the Ministry’s e-formulary for a listing of Limited Use (LU) criteria for Neupogen. Effective December 22, 2016, the subsequent entry biologic (SEB) filgrastim as Grastofil® is funded under the Ontario Drug Benefit (ODB) Program as a general benefit (GB). Please refer to the e-formulary for funded strengths. |
| Unclassified EAP Drugs | These drugs are not currently listed in the Exceptional Access Program Reimbursement Criteria for Frequently Requested Drugs – January 1, 2025 Edition Physicians may wish to contact the EAP directly by phone at 416-327-8109 or 1-866-811-9893 or by email at EAPFeedback.MOH@ontario.ca to see if an unlisted drug product and/or indication may be considered for EAP funding. |